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Measuring Treatment Outcomes in Women With Vulvodynia
Gary Ventolini
Abstract
Vulvodynia or vulvar pain syndrome is a chronic, heterogeneous, 
and multifactorial gynecological condition with an estimated prev-
alence of 9 - 12%, broad and substantial effect on quality of life due 
to physical disabilities, psychological distress and sexual dysfunc-
tion. A rationale therapeutic approach for the treatment of vulvo-
dynia is still under investigation. A review of treatment modalities 
proposed by most of the clinicians involved in managing these pa-
tients advocated initially utilizing non-invasive therapies and then 
to proceed gradually to more aggressive therapies. A multidisci-
plinary approach that includes behavioral science and neuroimag-
ing is required and recommended. Additionally a team approach 
should be utilized to test and evaluate therapies including pelvic 
ﬂ  oor physiotheraphy, psychotherapy, microbiology and pharmacol-
ogy. It is my hope that this review will assist in the understanding of 
vulvodynia and its measuring treatment outcomes and will provide 
a thrust in the right direction to once and for all clarify this complex 
multifactorial disorder affecting women.
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Introduction
Vulvodynia or vulvar pain syndrome is a chronic, hetero-
geneous, and multifactorial gynecological condition with an 
estimated prevalence of 9 - 12%, broad and substantial effect 
on quality of life due to physical disabilities, psychologi-
cal distress and sexual dysfunction [1, 2]. Fifteen percent of 
women seen in the generalist practitioners’ ofﬁ  ce have re-
ported pain on palpating areas of the vulvar vestibule. The 
condition may affect up to eighteen percent of the female 
population that includes Caucasians, African Americans, Af-
ricans and Hispanic women, particularly those who are sex-
ually active. Women who present symptoms of vulvodynia 
vary in age between 16 to 80 years. The majority is aged be-
tween 20 and 50 [3]. The current and most widely accepted 
classiﬁ  cation of vulvar pain as devised by the International 
Society for the Study of Vulvar Disease (ISSVD) recognizes 
vulvar pain related to a speciﬁ  c disorder (infections, inﬂ  am-
matory, neoplastic or neurologic) and vulvodynia (pain due 
to nonspeciﬁ  c etiology) [4].
Therapeutic Modalities
A rationale therapeutic approach for the treatment of vul-
vodynia is still under investigation. A review of treatment 
modalities proposed by most of the clinicians involved in 
managing these patients advocated initially utilizing non-
invasive therapies and then to proceed gradually to more ag-
gressive therapies.
Initial medical approaches include the avoidance of all 
skin and mucosal irritants (like soap, perfumes, and deodor-
ants), a diet containing low oxalates, scarce simple carbo-
hydrates, and oral supplementation of calcium citrate. Ad-
ditional measures are wearing cotton underwear, a trial of 
diverse relaxation techniques and psychological assessment 
with counseling and group support [5].
Topical treatments that have been reported as beneﬁ  cial 
in multiple studies include topical gel anesthetics and estro-
gen cream particularly in perimenopausal women. Regional 
therapies including pudendal nerve block and pelvic ﬂ  oor 
muscle rehabilitation with or without biofeedback have also 
been recommended [6, 7].
Physical therapy has also shown to be effective in the 
treatment of vulvodynia [8]. It involves the evaluation of the 
patient pelvic musculature, joints, fascia and tendons. The 
function of other related organs such as bowel and bladder 
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is evaluated as well. Most therapies employ a weekly one to 
two hour session focused on exercise for the pelvic ﬂ  oor and 
girdle, soft tissue mobilization, joint manipulation, muscle 
relaxation and general tone balance. However, standardiza-
tion regarding the effective treatment approach is inexistent 
among therapists therefore outcomes cannot be accurately 
validated nor reproduced [9].
Because histological features of the vulvar epithelium 
can show an increased density of neural tissue and nonspe-
ciﬁ  c inﬂ  ammation, neuromodulators have been used. Oral 
medications include tricyclic antidepressants like amitripti-
line, nortriptiline, and anticonvulsants like gabapentin. The 
above medications are usually initiated at a low dose and are 
increased over 2 - 4 week period. Opiates should be utilized 
only for short periods in acute settings and are not recom-
mended as maintenance therapy [10].
Surgical excision of the vulvar tissue involved should 
be considered in unresponsive cases [11, 12]. Success from 
vestibulectomy varies between 65 and 90 percent but long-
term relief is uncertain [13-15]. Generally, the vestibular epi-
thelium is removed from the hymeneal ring to the posterior 
fourchette. This can be done unilaterally or bilaterally based 
on patient’s pain distribution. It is however still considered 
to be the most efﬁ  cacious treatment option. Long-term fol-
low-up studies are required to fully assess risks, side effects 
and implications of this procedure in the psychosexual well-
being of the patient.
Laser ablation of the vulvar epithelium with the KTP-
Nd: YAG Laser and the CO2 Laser, has been promoted as 
an option to the more invasive vestibulectomy. Since an-
giogenesis and increased nerve density are characteristics 
of vulvodynia, the laser is used to disrupt these histologic 
abnormalities and to promote collagen remodeling without 
altering the macroscopic anatomy. The KTP-Nd: YAG Laser 
and pulsed-dye Laser offer the advantage of being absorbed 
more readily by vasculature therefore they promote colla-
gen remodeling. Results of Laser therapy for vulvodynia are 
comparable to vestibulectomy. Complete response has been 
reported in 62% and improvement in 92 % of the patients 
[14]. A recent report on KTP-Nd: YAG Laser use for vulvo-
dynia with a 2 year follow-up found that 68% of the patients 
reported less pain with sexual intercourse and 29% reported 
no beneﬁ  t [15].
Cognitive Behavior Therapy (CBT) has been applied 
to women with vulvodynia with encouraging results [16]. 
The objective of CBT is for the patient to learn to control 
their pain. Ter Kuile et al. found in a prospective, open-trial 
study that a reduction in dyspareunia was related to a general 
improvement in sexual functional level as well as increased 
control of the muscles of the pelvis [17]. Weijmar Schultz et 
al. have shown in a prospective, randomized study that CBT 
is comparable with surgery [18]. Bergeron and colleagues 
found in a small randomized, controlled study among 28 
women who had been allocated for CBT, electromyographic 
biofeedback or vestibulecttomy, that surgery primarily led to 
a reduction in dyspareunia. Two years of follow-up results 
from this study showed that, even though surgery was better 
than CBT with regard to the intensity of pain on touching the 
vestibulum, the effect of CBT and surgery were comparable 
after two years in terms of self-reported pain during coitus 
[19]. Recently Desorchers et al. suggested based on their 
study that fear-avoidance variables and pain self-efﬁ  cacy 
are signiﬁ  cant predictors of topical and CBT treatment out-
comes in women with provoked vestibulodynia (PV) [20].
Less well publicized methods of treatment such as acu-
puncture, local treatment using casaicin, ketoconazole, es-
trogen, steroids, niterfron, nifedipine and hypnosis are used 
to a lesser extent and with mixed results although without 
any major study reported. The clinician should be aware that 
a cure is not achieved in a short time even though the cor-
rect treatment is used. Improvement and reduction in pain 
may take several weeks. Therefore it is important to realisti-
cally inform and review the different options for treatment, 
to establish a multidisciplinary plan with a time frame and to 
assess results.
Measuring Treatment Outcomes
The ISSVD deﬁ  nition of vulvodynia emphasizes three car-
dinal points: the localization of the pain, the involvement of 
the sensory nerves, and the multidimensional clinical pic-
ture. However, the emotional and psychological factors are 
not mentioned in the deﬁ  nition. Because of that it has often 
been omitted to study the connection between the physiolog-
ical and the psychological factors that undoubtedly affect the 
condition.
Challenging features to appropriately measure treatment 
outcomes are: (1) the heterogeneous symptomatic manifesta-
tions, (2) the absence of a clear pathology, (3) the lack of an 
exclusively psychological explanation model, (4) the vari-
able presence of clinically recognized objective signs (red-
ness in the involved areas), and (5) the emotional superstruc-
ture that impacts vulvodynia.
Instruments Used to Measure Outcomes
  
The Vulvar Vestibulitis Clinical Trial, Development of the 
National Institutes of Health, was a randomized, placebo 
controlled, double-blinded clinical trial to study the clini-
cal efﬁ  cacy of four medical treatments for vulvar vestibu-
litis syndrome (localized vulvodynia): topical lidocaine, 
oral desipramine, combined lidocaine and desipramine, and 
placebo cream and tablets [21]. The duration of study drugs 
lasted 12 weeks with postintervention follow-up at 16, 26 
and 52 weeks. Clinical response was assessed by change in 
pain by numeric rating scale of a weekly Tampon Test com-
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pared with a number of measures with preexisting reliabil-
ity/validity data or prior published experience in vulvodynia 
clinical trials, including change in overall daily pain inten-
sity (24 hour numeric rating scale), the frequency of sexual 
intercourse (attempts per week), the change in intercourse 
pain numeric rating scale, vulvar algesiometer score, and the 
cotton swab test pain level by verbal reporting scale. In addi-
tion, during each study visit participants completed a battery 
of pain and health related quality-of-life measures recom-
mended by IMMPACT including: the Brief Pain Inventory, 
Short Form McGill Pain Questionair (SF-MPQ), Proﬁ  le of 
Mood States, and the Beck Depression Inventory. Therapeu-
tic response of desipramine/lidocaine was estimated from 
preliminary reported data from the same group.
To be included in the trial, participants needed to fulﬁ  ll 
Friedrich’s Criteria for the diagnosis of vulvodynia, includ-
ing tenderness localized within the vestibule conﬁ  rmed by 
the cotton swab test modiﬁ  ed from the technique of Bergeron 
et al. (Table 1).
Adapted from Murina and coworkers dyspareunia, burn-
ing and itching are as described by the patient [22]. The swab 
test is performed with a cotton swab touched to the vestibule, 
and the degree of erythema is determinded by visual inspec-
tion of the vestibule by the examiner, the higher the score, 
the more severe the symptoms.
A pain diary card is usually ﬁ  lled out during week dur-
ing the screening and baseline visit. Drug dose education 
phase treatment is initiated at a low daily dose for 2 weeks, 
increased to a medium for 2 weeks, and subsequently each 
dose for an additional week. The dosing schedule varies ac-
cording to the medication used from once daily to up to three 
times a day. Drug maintenance phase and the target mainte-
nance dose are tailored consequently. Dose tapering phase is 
usually necessary according to the pharmacokinetics of the 
medication used.
Pretreatment and posttreatment pain scores are mea-
sured on a discrete scale as follows: (1) the McGill Pain Rat-
ing Index, consisting of 15 pain descriptors ranging from 0 
(none) to 3 (severe) describing pain for the previous month; 
(2) the McGill Visual Analog Scale of overall pain intensity 
for the past month, ranging from 0 (no pain) to 10 (worst 
possible pain); (3) the McGill Pain Intensity Scale modiﬁ  ed 
to rate pelvic pain from 0 (no pain) to 5 (excruciating); (4) 
the Hamilton Depression Rating Scale (HAM-D), a standard 
interview-based measure of depression; and (5) the Hamil-
ton Anxiety Rating Scale (HAM-A), a standard interview-
based of anxiety [23].
The three-item subscale containing items such as “Rate 
the level of your pain at the present moment” on a scale of 0 
(no pain) to 6 (very intense pain) was used.
Studies by gynecologists obtained the following ratings 
intended to correspond with Friedrich’s three criteria for vul-
var vestibulitis: the Speculum Rating, the Cotton-swab Rat-
ing, and the Erythema (redness of the skin) Rating.
The Speculum Rating is a four-point rating (i.e., absent 
(0), mild (1), moderate (2), and severe (3)), based on pain 
provoked at the introitus with speculum insertion. Narrow (2 
cm width), prewarmed, metal speculums were used. Scores 
are calculated by averaging the two baseline rating. This 
measure has been shown to be valid and reliable [24].
The Erythema Rating is a four-point rating, using the 
same scale above, for the presence and degree of erythema.
The Cotton-swab Rating involves pain ratings of point 
tenderness provoked by cotton-swab palpation at each of six 
sites within the vulvar vestibule (i.e., clitoris, perineum, right 
and left labia minora, and right and left labia majora) and 
rated on a four-point scale: absent (0), mild (1), moderate 
(2), and severe (3). The measure has been shown to be valid 
and reliable [25].
The Pain Severity Subscale of the West Haven-Yale 
Multidimensional Pain Inventory (MPI) is a widely used 
multidimensional self-report instruments designed to assess 
chronic pain that has demonstrated reliability and validity 
[26].
The McGill Pain Questionnaire (MPQ) is a widely used 
measure of pain severity. The questionnaire comprises 20 
sets of 3 - 5 descriptive words placed in order of increas-
ing severity or intensity. The measure is used to assess three 
domains of pain: sensory, affective and evaluative. Subjects 
are instructed to circle one word within each set that best de-
scribes their pain. The measure has demonstrated acceptable 
reliability, and face, construct, discriminant and concurrent 
Table 1. Friedrich Criteria for Vulvodynia Diagnosis
Score Dyspareunia Burning Itching Swab Test Erythema
0 Absent Absent Absent Negative Absent
1 Mild Pain Mild Mild Weakly Positive Mild
2 Persistent Moderate Moderate Positive Moderate
3 With Intercourse Severe Severe Strongly Positive Severe
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validity [27]. Total scores range from 0 to 78.
Emotional function
The Beck Depression Inventory (BDI) is a psychometrically 
sound, widely used inventory of the cognitive, affective, 
motivational, and somatic symptoms of depression with 
adequate internal consistency, acceptable short-term test-
retest reliability and good convergent validity with clinician 
ratings of depressive symptoms [28]. Higher scores reﬂ  ect 
greater depressive symptom severity.
The Pain Anxiety Symptoms Scale (PASS) is a 40-item 
measure of fear of pain intended to measure four aspects of 
anxiety associated with clinical pain symptoms: cognitive 
anxiety, fear of pain, escape and avoidance, and physiologi-
cal anxiety. The measure has been shown to be internally 
consistent and valid [29]. The frequency of each item (e.g., 
I think that if my pain gets too sever, it will never decrease) 
is rated on a six-point scale from 0 (never) to 5 (always). 
Higher scores reﬂ   ect more frequent and more numerous 
anxiety responses.
Treatment acceptability
Global treatment improvement is measured with the single 
item, “Up to what point do you feel your vulvar pain has im-
proved following the treatment you received in this study?” 
Responses include: 0, worse; 1, no improvement; 2, little 
improvement; 3, moderate improvement; 4, great improve-
ment; 5, complete cure.
Treatment satisfaction is measured with the single-item, 
“On a scale of 0 - 10, how would you rate your overall satis-
faction with the treatment you received?” Responses ranged 
from “completely dissatisﬁ  ed” to “completely satisﬁ  ed”.
Treatment credibility is measured with a ﬁ  ve-item scale 
adapted from Borkovec and Nau [30] and completed after 
treatment sessions one and ten (Le. Post-treatment). Items 
such as “How logical does the treatment seem to you?” were 
rated from 0 to 10.
Sexual function
The Female Sexual Function Index (FSFI) is a 19-item mul-
tidimensional, self-report measure of sexual function. The 
measure has received empirical support for its reliability in 
several patient samples and for its ability to discriminate 
between samples of women with sexual dysfunction and 
healthy samples [31].
The FSFI includes both frequency items (“Over the past 
4 weeks, how often did you experience discomfort or pain 
during vaginal penetration?”) and intensity items (“Over the 
past 4 weeks, how would you rate your level (degree) of dis-
comfort or pain during or following vaginal penetration?”). 
Higher scores reﬂ  ect better functioning.
Bullet Points
•  Despite many published studies on vulvodynia treat-
ment during the past two decades, it remains difﬁ  cult to 
recommend on speciﬁ  c treatment for any given patient.
•  Based on recent prospective and randomized studies, 
attempts to recommend more evidence-based treatment 
are in place.
•  In small non-randomized clinical trials, daily application 
of topical lidocaine and local corticosteroid-lidocaine 
injections provide considerable relief to women with 
provoked vestibulodynia.
•  Multiple published studies have demonstrated the ben-
eﬁ  ts of using pain medications like antidepressant, try-
cyclics and anticonvusants alone or combined.
•  Vestibulectomy, evaluated in a randomized study, seems 
to be the most efﬁ  cacious treatment option. Long-term 
follow-up studies are required to fully assess risks, side 
effects and implications of this procedure in the psycho-
sexual well-being of the patient.
•  A multidisciplinary approach that includes gynecology, 
microbiology, genetics, proteomics, biochemistry, phar-
macology, behavioral science and neuroimaging is re-
quired and recommended to conclusively elucidate the 
pathophysiology of vulvodynia and to device the most 
appropriate therapy.
Expert Opinion
My opinion, shared by a number of authors, includes the hy-
pothesis that vulvodynia is a pathological alteration at the 
vaginal vestibule and the vulvovaginal milieu involving the 
mucosa, subcutaneous tissue, accessory sexual glands with 
their related circulatory and nervous system. This altera-
tion is probably due to an insult, inﬂ  ammation or infection 
and it is sustained by biological and chemical changes with 
consequent dysfunction of the vaginal vestibule, Bartholin, 
and Skene glands secreting function. These changes may 
be initiated by an insult or preceding infection or inﬂ  am-
mation by bacteria, fungi, or virus that results in hypersen-
sitivity leading to pelvic ﬂ  oor muscle dysfunction and re-
current pain. Vulvodynia may have an immune and genetic 
predisposition component leading to impaired neurological 
modulation of sensory C-afferent nociceptive processing and 
pathophysiologically distorted biochemical, immunological 
and behavioral responses to pain. There may be a potential 
role of psychosocial factors involved as it is the case like in 
other chronic pain conditions. Therefore a multidisciplinary 
approach that includes gynecology, microbiology, genet-
ics, proteomics, biochemistry, pharmacology, behavioral 
science, and neuroimaging is required and recommended. 
Additionally a team approach should be utilized to test and 
evaluate therapies including pelvic ﬂ  oor  physiotheraphy, 
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psychotherapy, microbiology and pharmacology [19, 32-37].
This multidisciplinary approach will certainly allow us 
to frame a more speciﬁ  c and testable hypotheses regarding 
the etiology of this condition and to evaluate the most likely 
and signiﬁ  cant factors leading to vulvodynia, furthermore it 
will certainly allow us to exclude other factors and to quality 
comorbid and psychiatric factors, triggers, and topical en-
vironment conditions favoring, promoting or perpetuating 
this condition. It is my hope that this review will assist in 
the understanding of vulvodynia and its measuring treatment 
outcomes and will provide a thrust in the right direction to 
once and for all clarify this complex multifactorial disorder 
affecting women.
Multidisciplinary approach to evaluate patients with vul-
vodynia
1.  The interaction of environment, psychosocial and co-
morbid conditions implicated in  vulvodynia.
2.  The role that any insult or infections plays in the preced-
ing of this condition.
3.  The presence of any biochemical changes in the vulvo-
vaginal milieu, and Bartholin and Skene glands in these 
patients.
4.  The role of pelvic ﬂ  oor muscles and topical contributing 
factors.
5.  The existence in these patients of any genetic predispo-
sition that could impair the neurological modulation of 
sensory nociceptive processing.
6.  The role of any biochemical, immunological or behav-
ioral distortion in the response to pain.
7.  Genetic testing to ascertain susceptibility genes involved 
including serological determination of behavioral mak-
ers.
8.  Functional MRI (fMRI) to assess the functional and 
anatomical characteristics of subjects with vulvodynia 
compared to healthy women.
9.  How current medications used in the treatment of vulvo-
dynia target speciﬁ  c areas of the brain involved in pain 
responses.
10. The presence of any particular personality, behavioral 
feature or psychological factors involved in the propen-
sity, instigation, promotion and perpetuation of chronic 
pain conditions like vulvodynia.
11. Evaluation of the patient’s response to pain (subjec-
tive, objective and the brain) prior to treatment and after 
pharmacological therapy used for vulvodynia.
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